GVS advice GLP-1 receptor agonists extension further conditions

The National Health Care Institute has completed its assessment whether the further conditions of the GLP-1 agonists could be extended. This is a group assessment. The National Health Care Institute advises the Minister to extend the reimbursement conditions for dulaglutide, exenatide, liraglutide and semaglutide. The further condition for lixisenatide should not be extended.

Indication for which extension of the reimbursement conditions is requested

The indication to be assessed is for patients with diabetes mellitus type 2 (DM2) and a very high risk of cardiovascular disease where glucose levels cannot be adequately regulated with a SGLT-2 inhibitor or if the use of a SGLT-2 inhibitor is contraindicated.

National Health Care Institute's advice

The National Health Care Institute advises the Minister to extend the reimbursement conditions for dulaglutide, exenatide, liraglutide and semaglutide. The further condition for lixisenatide should not be extended. The proposed extension is accompanied by additional costs.

Extension of the further condition for dulaglutide, exenatide, liraglutide and semaglutide:
In addition to an SGLT2 inhibitor and metformin, or when an SGLT2 inhibitor is contraindicated, added to the standard treatment, for an insured person with diabetes mellitus type 2 with a very high risk of cardiovascular disease (according to the NHG guideline for Diabetes Mellitus type 2):

  1. With previously proven cardiovascular diseases; and/or
  2. chronic kidney disease.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.